Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, BioCryst Pharmaceuticals's enterprise value is $2,908.8 Mil.
BioCryst Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-377.5 Mil. Therefore, BioCryst Pharmaceuticals's EV-to-EBITDA for today is -7.71.
The historical rank and industry rank for BioCryst Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
BCRX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -92.2 Med: -9.38 Max: 187.22
Current: -7.71
During the past 13 years, the highest EV-to-EBITDA of BioCryst Pharmaceuticals was 187.22. The lowest was -92.20. And the median was -9.38.
BCRX's EV-to-EBITDA is ranked worse than 100% of 745
companies
in the Drug Manufacturers industry
Industry Median: 12.91
vs BCRX: -7.71
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BioCryst Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
BioCryst Pharmaceuticals's share price for today is $9.165.
BioCryst Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.780.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, BioCryst Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioCryst Pharmaceuticals EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioCryst Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where BioCryst Pharmaceuticals's EV-to-EBITDA falls into.
BioCryst Pharmaceuticals's current Enterprise Value is $2,908.8 Mil.
BioCryst Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-377.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioCryst Pharmaceuticals (BCRX) has a EV-to-EBITDA of -7.71 as of Jul. 30, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on BioCryst Pharmaceuticals. According to the industry distribution chart, BioCryst Pharmaceuticals ranks #999999 out of 745 companies in the Drug Manufacturers industry.
Is BioCryst Pharmaceuticals' EV-to-EBITDA too high?
BioCryst Pharmaceuticals' current EV-to-EBITDA is -7.71. Based on the distribution chart, BioCryst Pharmaceuticals ranks #999999 out of 745 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, BioCryst Pharmaceuticals has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioCryst Pharmaceuticals' EV-to-EBITDA compare to PBH and SUPN?
According to the Drug Manufacturers industry distribution chart, BioCryst Pharmaceuticals ranks #999999 out of 745 companies for EV-to-EBITDA. This places BioCryst Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBITDA is 12.91. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.91, based on 745 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on BioCryst Pharmaceuticals. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioCryst Pharmaceuticals's current EV-to-EBITDA is -7.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioCryst Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, BioCryst Pharmaceuticals (BCRX) is currently considered Modestly Undervalued. The stock's GF Value™ is $12.21, compared to a current price of $9.17 — trading 24.9% below its estimated fair value. The current EV-to-EBITDA is -7.71. BioCryst Pharmaceuticals' overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For BioCryst Pharmaceuticals (BCRX), the current EV-to-EBITDA is -7.71 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioCryst Pharmaceuticals (BCRX) Overvalued in 2026?
Based on GuruFocus' analysis, BioCryst Pharmaceuticals stock appears to be undervalued.
The current stock price of $9.17 is trading 24.9% below its estimated GF Value™ of $12.21.
GuruFocus considers BioCryst Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for BCRX:
EV-to-EBITDA: -7.71
GF Value™: $12.21 vs. price of $9.17 (24.9% below fair value)
No single metric tells the full story. See the BCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
65GF Score
Get the complete analysis for BCRX
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BCRX has been successfully added to your 
